Alphatec Hlds (ATEC) Stock Forecast & Price Target

Alphatec Holdings is viewed positively because, despite the 1Q26 revenue miss to $192M versus $197M consensus and a wider net loss of $0.22 per share versus $0.02 expected, the core spine franchise still posted 13.6% year-over-year sales growth, strong 21% surgical volume growth, and continued U.S. share gains. The main weakness came from EOS, where revenue fell to $14M, down 17.6% year over year, due to poor sales execution and missed hardware sales, but management has already initiated a sales force and operations revamp while still reaffirming 2026 adjusted EBITDA guidance of $134M and free cash flow guidance of $20M. The outlook remains constructive because gross margin improved to 71.0%, adjusted EBITDA of $20.7M beat expectations by $6.5M on disciplined OpEx, free cash use was only $11M, and the analysis argues the current stock decline reflects transient EOS issues rather than a broken long-term trajectory, with profitability improvement expected to continue into 2027 and beyond.

Alphatec Holdings is facing a negative outlook because the latest results and guidance show that revenue growth is increasingly dependent on a troubled EOS franchise, which missed expectations due to execution problems around installation timing, sales coverage, and downstream marketing rather than durable demand. Although the core surgical business remains healthy with 20%+ case volume and surgeon addition growth, total sales guidance was cut by $8M to $882M (+15% y/y), highlighting that weaker top-line execution is offsetting otherwise solid franchise momentum. Even with management reaffirming adj. EBITDA of $134M and full-year FCF of $20M, the combination of EOS softness, mix headwinds, and elevated commercial, regulatory, financial, and intellectual property risks suggests the company’s fundamentals are not yet strong enough to support a constructive view.